Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1633 1642 1646
This examiner grants 58% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 16345124 | EXOSOMES AND USES THEREOF | Final Rejection | President and Fellows of Harvard College |
| 17115360 | Screening of cell clones expressing polygenic transgenes through non-antibiotic dependent positive selection | Non-Final OA | ImmunityBio, Inc. |
| 18335515 | PRECURSOR PROTEINS AND KIT FOR TARGETED THERAPY | Non-Final OA | Hoffmann-La Roche Inc. |
| 17784891 | METHOD AND COMPOSITION FOR ENHANCING THE IMMUNE RESPONSE | Non-Final OA | Northwestern University |
| 17033050 | CELL-BASED CANCER VACCINES AND CANCER THERAPIES | Non-Final OA | Massachusetts Institute of Technology |
| 18016209 | METHODS AND COMPOSITIONS FOR TREATMENT AND PREVENTION OF CORONAVIRUS INFECTION | Non-Final OA | Dana-Farber Cancer Institute, Inc. |
| 18268575 | STRUCTURE-BASED DESIGN AND DISCOVERY OF LONG-ACTING COCAINE HYDROLASE MUTANTS WITH IMPROVED BINDING AFFINITY TO NEONATAL FC RECEPTOR FOR TREATMENT OF SUBSTANCE USE DISORDERS AND ORGANOPHOSPHORUS TOXICITY | Non-Final OA | University of Kentucky Research Foundation |
| 18339565 | CD20 THERAPIES, CD22 THERAPIES, AND COMBINATION THERAPIES WITH A CD19 CHIMERIC ANTIGEN RECEPTOR (CAR)-EXPRESSING CELL | Final Rejection | The Trustees of the University of Pennsylvania |
| 18148807 | TREATMENT OF CANCER USING A CD123 CHIMERIC ANTIGEN RECEPTOR | Non-Final OA | The Trustees of the University of Pennsylvania |
| 17781945 | NANOPARTICLE COMPOSITIONS AND METHODS OF USE | Final Rejection | The Trustees of the University of Pennsylvania |
| 18342884 | PEPTIDE ANALOGS CAPABLE OF ENHANCING STIMULATION OF A GLIOMA-SPECIFIC CTL RESPONSE | Non-Final OA | University of Pittsburgh - Of the Commonwealth System of Higher Education |
| 17290705 | SELECTION OF IMPROVED TUMOR REACTIVE T-CELLS | Non-Final OA | Iovance Biotherapeutics, Inc. |
| 17727142 | METHOD FOR SINGLE-BASE GENOME EDITING USING CRISPR/CPF1 SYSTEM AND USES THEREOF | Non-Final OA | CHUNG ANG UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION |
| 17753119 | CHIMERIC COSTIMULATORY RECEPTORS AND METHODS AND USES THEREOF | Non-Final OA | McMaster University |
| 18046173 | COMBINATION | Final Rejection | AstraZeneca AB |
| 18373648 | ANTI-PD-1/LAG-3 BISPECIFIC ANTIBODIES AND USES THEREOF | Non-Final OA | Incyte Corporation |
| 18106531 | Methods for Reducing Infusion-Related Reactions in Patients Treated with EGFR/Met Bispecific Antibodies | Final Rejection | Janssen Biotech, Inc. |
| 17919178 | FLT3-TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED CELLS FOR TREATMENT OF FLT3-POSITIVE MALIGNANCIES | Final Rejection | City of Hope |
| 18261854 | ACE2-RECEPTOR ECTODOMAIN FUSION MOLECULES AND USES THEREOF | Non-Final OA | National Research Council of Canada |
| 17775791 | COBICISTAT FOR PREVENTION AND/OR TREATMENT OF CORONAVIRUS INFECTIONS | Final Rejection | UNIVERSITÄT HEIDELBERG |
| 17770978 | METHOD FOR PRODUCING MONOVALENT CCAP PRODUCT | Non-Final OA | Kagoshima University |
| 18044365 | CORONAVIRUS-DERIVED RECEPTOR-BINDING DOMAIN VARIANT HAVING REDUCED ACE2-BINDING AFFINITY AND VACCINE COMPOSITION COMPRISING THE SAME | Non-Final OA | GI CELL, INC. |
| 18500706 | COMBINATION THERAPIES FOR TREATMENT OF BCMA-RELATED CANCERS AND AUTOIMMUNE DISORDERS | Non-Final OA | Fred Hutchinson Cancer Center |
| 18357452 | METHODS AND COMPOSITIONS COMPRISING FUSION PROTEINS FOR THE IDENTIFICATION OF IMMUNOTHERAPY CELLS | Non-Final OA | Lankenau Institute for Medical Research |
| 18047928 | COMPOSITIONS AND METHODS FOR LONG-LASTING GERMINAL CENTER RESPONSES TO A PRIMING IMMUNIZATION | Final Rejection | La Jolla Institute for Immunology |
| 18489222 | COMBINATIONS OF CHECKPOINT INHIBITORS AND THERAPEUTICS TO TREAT CANCER | Final Rejection | RevImmune, Inc. |
| 18261155 | METHOD FOR PREDICTING RISK FOR THROMBOSIS IN CANCER PATIENT USING SOLUBLE CLEC2 | Non-Final OA | PHC Corporation |
| 18268434 | PHARMACEUTICAL COMPOSITION FOR AMELIORATING MALIGNANT DISEASES | Non-Final OA | KINKI UNIVERSITY |
| 18274118 | PREVENTION OF POSTERIOR CAPSULAR OPACIFICATION (PCO) WITH INTEGRIN AVB8 BLOCKING ANTIBODY | Non-Final OA | UNIVERSITY OF DELAWARE |
| 18273509 | ANTI-HER-2/TROP-2 CONSTRUCTS AND USES THEREOF | Non-Final OA | BiOneCure Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy